Cancer Test May Offer High-Risk Groups Quick, Affordable Screening For Tumors

New Technique Is Among The First Envisioned For A Wide Variety Of Tumor Types

Johns Hopkins researchers have developed a new test that may allow doctors to regularly and quickly check for early cancers in patients at risk for developing cancer due to genetic or environmental factors.

The test temporarily slows DNA production in cancer cells, causing some elements of DNA to accumulate in the blood. When these materials are excreted in large amounts in urine, they indicate the presence of cancer.

Hopkins researchers found 8 of 11 cancer patients tested positive for cancer using the new technique. The patients, who were diagnosed with cancer before taking the new test, had a variety of tumors. The results of the study, supported in part by an American Society of Clinical Oncology Young Investigator Award and by the National Institute of Child Health and Human Development, appear in the May issue of In Vivo.

Scientists say initial results are promising but the test must be validated by additional research.

"We must study larger groups of patients, and if these preliminary results are confirmed, doctors possibly could use the test for the early detection of tumors in patients at risk for cancer," says Saul Brusilow, M.D., professor of pediatrics. "It might also be useful as a post-surgical test for residual cancer cells."

For the test, patients gave a baseline urine sample and took one allopurinol pill. This drug, ordinarily used to treat gout, also temporarily interferes with the production of elements of DNA called pyrimidines. Patients' urine was then collected in four periods over the next 24 hours and tested for increased levels of orotidine and orotate, two compounds used to build pyrimidines.

Increases in the levels of these compounds were surprisingly large.

"These dramatic changes suggest that

Contact: Michael Purdy
Johns Hopkins Medical Institutions

Page: 1 2

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Cancer gene MYC emerging as key research target
5. Cancer patient, heal thyself
6. USC researcher named General Motors Cancer Research Scholar
7. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
8. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
11. National Cancer Gene Therapy Foundation gives $4.0 million in research grants

Post Your Comments:

(Date:3/27/2019)... ... ... Evan Holden , a shareholder in the Atlanta office ... National Academy of Sciences (NAS) Roundtable on Biomedical Engineering Materials Applications (BEMA), March 25 ... Pharmaceutical, Medical Device & Health Care Litigation Practice , addressed, “Medical Device Liability—How ...
(Date:3/25/2019)... ... March 25, 2019 , ... Ambry Genetics ... genetic testing, today announced a new laboratory services agreement with Clovis Oncology Inc., ... Through this laboratory services agreement, Ambry Genetics and Clovis Oncology seek to ...
(Date:3/23/2019)... , ... March 22, 2019 , ... ... for Next Generation Sequencing (NGS) sample preparation. RhinoSeq employs a proprietary kit chemistry ... The five-tube kit is comprised of preformatted master mixes for a simple, fast, ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... SANTA BARBARA, Calif. (PRWEB) , ... April 09, ... ... global professional services firm focused on increasing the capacity of life sciences organizations ... to its Cloud Assurance platform in the past 12 months. , ...
(Date:4/9/2019)... ... April 09, 2019 , ... The American Society of Gene & ... leadership team, including a new addition to the presidential line of succession, at the ... join the Society's leadership team for a three-year term (2019-2021). , All five incoming ...
(Date:4/8/2019)... ... 2019 , ... US Capital Global Securities , an affiliate of US ... the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of ... sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a ...
(Date:4/4/2019)... , ... April 02, 2019 , ... ... solutions, announced it would be releasing it’s latest field-ready solution for performing PCR, ... Biomeme’s next-gen thermocycler Franklin™ pays homage to Rosland Franklin, an English chemist and ...
Breaking Biology Technology:
Cached News: